The Children's Hospital at Westmead, NSW, Australia.
Dev Med Child Neurol. 2010 Apr;52(4):328-30. doi: 10.1111/j.1469-8749.2010.03613.x. Epub 2010 Feb 12.
Mitofusin 2, a large transmembrane GTPase located in the outer mitochondrial membrane, promotes membrane fusion and is involved in the maintenance of the morphology of axonal mitochondria. Mutations of the gene encoding mitofusin 2 (MFN2) have recently been identified as the cause of approximately one-third of dominantly inherited cases of the axonal degenerative forms of Charcot-Marie-Tooth disease (CMT type 2A) and of rarer variants. The latter include a severe, early-onset axonal neuropathy, which may occur in autosomal dominant or recessive forms, as well as some instances associated with pyramidal tract involvement (CMT type 5), with optic atrophy (CMT type 6), and, occasionally, with alterations of cerebral white matter. All individuals with a dominantly or recessively inherited or otherwise unexplained, chronic progressive axonal degenerative polyneuropathy should be tested for mutations of MFN2.
线粒体融合蛋白 2(Mitofusin 2,MFN2)是一种位于线粒体外膜的大型跨膜 GTP 酶,可促进线粒体膜融合,并参与维持轴突线粒体的形态。编码线粒体融合蛋白 2(MFN2)的基因突变最近被确定为大约三分之一的常染色体显性遗传性轴索性腓骨肌萎缩症(CMT 型 2A)和更罕见变异型的病因。后者包括严重的早发性轴索性神经病,其可能以常染色体显性或隐性形式发生,也可能与锥体束受累(CMT 型 5)、视神经萎缩(CMT 型 6)以及偶尔与脑白质改变相关(CMT 型 6)。所有具有常染色体显性或隐性遗传或其他不明原因的慢性进行性轴索性退行性多发性神经病的个体均应检测 MFN2 基因突变。